A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Trial Profile

A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Ixabepilone (Primary) ; Carboplatin; Paclitaxel; Temsirolimus
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2018 Primary endpoint (Number of Participants Who Progressed or Died by 25 Months From Enrollment [progression free survival]) has not been met, according to the results published in the Gynecologic Oncology
    • 24 May 2018 Results assessing efficacy and safety published in the Gynecologic Oncology
    • 02 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top